The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

Launched by JASPER GERRITSEN · Feb 21, 2024

Keywords

ClinConnect Summary

The RECSUR study is looking at the best ways to treat patients whose glioblastoma, a type of brain cancer, has come back after initial treatment. The researchers want to compare two approaches: one group of patients will have surgery to remove the tumor, while another group will receive the best available non-surgical treatment. They hope to find out which option helps patients live longer and maintain their quality of life. The study will also gather information about any potential side effects and how patients feel after treatment.

To participate in this study, you must be between 18 and 90 years old and have a recurring glioblastoma that is eligible for surgery. You will need to provide written consent to join. The study is expected to last about five years, with participants being followed for one year after their treatment. If you or someone you know is dealing with recurrent glioblastoma, this trial could be an opportunity to help researchers understand the best treatment options available.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years and ≤90 years
• • 2. Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastoma based on the WHO 2021 classification for glioma
• • 3. The tumor is suitable for resection (according to neurosurgeon)
• • 4. Written informed consent
• Exclusion Criteria:
• • 1. Tumors of the cerebellum, brainstem, or midline
• • 2. Medical reasons precluding MRI (e.g., pacemaker)
• • 3. Inability to give written informed consent
• • 4. Secondary high-grade glioma due to malignant transformation from low-grade glioma
• • 5. Clinical data unavailable for the newly diagnosed setting